Research Study Findings from Deakin University Update Understanding of Anxiety Disorders [The Silexan in the Treatment Of Posttraumatic stress disorder (STOP) trial: protocol for a 12-week randomised controlled trial of adjunctive Silexan for...].

This article focuses on the Silexan in the Treatment Of Posttraumatic stress disorder (STOP) trial, a 12-week randomized, placebo-controlled study investigating the effectiveness of Silexan—an oral lavender oil preparation—in treating posttraumatic stress disorder (PTSD). Conducted by Deakin University and funded by the U.S. Department of Defense, the trial enrolls adults in Australia diagnosed with PTSD and measures changes in symptom severity alongside secondary outcomes such as anxiety, depression, sleep quality, and physiological data. Silexan, known for its safety and tolerability, has shown promise in treating generalized anxiety disorder and depression, and this trial aims to assess its potential as an adjunctive PTSD treatment. The STOP trial is registered on clinicaltrials.gov (ID: NCT06412757) and could facilitate rapid clinical application if results demonstrate efficacy. [Extracted from the article]